Breast cancer (invasive) · line 3 · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 3 |
|---|---|
| Track | standard |
| Linked regimen | None |
| ID | IND-BREAST-TNBC-3L-POST-SACI-POST-T-DXD |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-BREAST |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-KEYNOTE-355-CORTES-2020 SRC-NCCN-BREAST-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. 3L+ salvage pathway for TNBC after immunochemo 1L + ADC 2L exhaustion. Trial enrollment strongly preferred. Multiple sequential single-agent chemo options exist but no dedicated REG- entity for each — flagged for PROD-2.
Used By
No reverse references found in the YAML corpus.